Brokerages Set Inogen Inc (NASDAQ:INGN) Target Price at $61.75

Shares of Inogen Inc (NASDAQ:INGN) have been assigned a consensus recommendation of “Hold” from the eleven research firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $61.75.

A number of research firms have recently weighed in on INGN. Needham & Company LLC cut Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Stifel Nicolaus cut Inogen from a “buy” rating to a “hold” rating and lowered their price objective for the company from $85.00 to $48.00 in a research report on Wednesday, August 7th. BidaskClub cut Inogen from a “sell” rating to a “strong sell” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. cut Inogen from a “neutral” rating to an “underweight” rating and set a $72.00 price target on the stock. in a report on Wednesday, July 3rd. Finally, Leerink Swann cut Inogen from an “outperform” rating to a “market perform” rating in a report on Thursday, August 8th.

Shares of INGN stock traded up $0.53 during trading hours on Monday, reaching $49.51. 389,367 shares of the company traded hands, compared to its average volume of 567,912. Inogen has a 12-month low of $41.19 and a 12-month high of $205.34. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.35 and a quick ratio of 6.82. The company has a market cap of $1.09 billion, a P/E ratio of 21.53, a P/E/G ratio of 4.09 and a beta of 1.51. The firm has a 50-day moving average price of $47.42 and a 200 day moving average price of $61.93.

Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Wednesday, August 7th. The medical technology company reported $0.45 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.50 by ($0.05). Inogen had a net margin of 11.24% and a return on equity of 13.34%. The company had revenue of $101.10 million for the quarter, compared to analysts’ expectations of $106.88 million. During the same period in the previous year, the firm earned $0.65 earnings per share. The firm’s quarterly revenue was up 3.9% on a year-over-year basis. Sell-side analysts predict that Inogen will post 1.09 EPS for the current year.

In other Inogen news, Director Loren L. Mcfarland purchased 1,000 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were bought at an average cost of $42.93 per share, with a total value of $42,930.00. Following the acquisition, the director now owns 4,481 shares in the company, valued at $192,369.33. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Heath Lukatch purchased 2,000 shares of the stock in a transaction that occurred on Thursday, August 15th. The stock was acquired at an average cost of $43.01 per share, for a total transaction of $86,020.00. Following the completion of the acquisition, the director now owns 5,481 shares in the company, valued at approximately $235,737.81. The disclosure for this purchase can be found here. 4.54% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Marshall Wace LLP raised its holdings in shares of Inogen by 180.2% during the 1st quarter. Marshall Wace LLP now owns 55,580 shares of the medical technology company’s stock worth $5,301,000 after acquiring an additional 35,747 shares in the last quarter. Polen Capital Management LLC raised its holdings in shares of Inogen by 8.6% during the 2nd quarter. Polen Capital Management LLC now owns 5,083 shares of the medical technology company’s stock worth $339,000 after acquiring an additional 404 shares in the last quarter. Aperio Group LLC raised its holdings in shares of Inogen by 10.8% during the 2nd quarter. Aperio Group LLC now owns 12,818 shares of the medical technology company’s stock worth $856,000 after acquiring an additional 1,254 shares in the last quarter. BBT Capital Management LLC purchased a new stake in shares of Inogen during the 2nd quarter worth approximately $442,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of Inogen by 247.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 44,035 shares of the medical technology company’s stock worth $2,883,000 after acquiring an additional 31,366 shares in the last quarter.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Further Reading: What is a back-end load?

Analyst Recommendations for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.